Akari Therapeutics PLC (AKTX) Stock Analysis

AI analysis of Akari Therapeutics PLC (AKTX)

Hold

Currently, Akari Therapeutics PLC (AKTX) is not a good buy. The stock is trading at $7.37, significantly below its 52-week high of $29.32, indicating a substantial decline of 70.66% over the past year. The RSI is at 38.906, suggesting it is nearing oversold territory but not yet a strong buy signal. Furthermore, the forward P/E is 0, reflecting no earnings expected in the near term, which raises concerns about its profitability and financial health. The main risk is the negative net income, which reached -14,455,000 USD in Q1 2026, indicating ongoing financial struggles.

Analyst Ratings (3)

-54.82% Downside

Buy

2 Buy

1 Hold

0 Sell

Current: 7.37

Low

1.00

Average

3.33

High

7.00

Alliance Global

Buy

$7

2026-09-16

Alliance Global

2026-09-16

Price Target

$7

Buy

Maxim

Buy

$30

2026-07-20

Maxim

2026-07-20

Price Target

$30

Buy

Maxim

Hold

—

2026-04-09

Maxim

2026-04-09

Price Target

—

Hold

Maxim

Hold

—

2026-04-08

Maxim

2026-04-08

Price Target

—

Hold

H.C. Wainwright

Buy

$27

2026-04-01

H.C. Wainwright

2026-04-01

Price Target

$27

Buy

See All Ratings

Valuation Metrics

The current forward P/E ratio for Akari Therapeutics PLC (AKTX) is 0.00, compared to its 5-year average forward P/E of 20.17.

Forward P/E

Fair

5Y Average P/E

20.17

Current P/E

0.00

Overvalued

137.52

Undervalued

-97.19

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Fair

5Y Average P/S

0.36

Current P/S

0.00

Overvalued

2.17

Undervalued

-1.45

Alphio AI Price Scenarios for AKTX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%AKTX

$1.46

Scenario price

B

Base

Base · 50%AKTX

$1.24

Scenario price

B

Bear

Bear · 25%AKTX

$1.21

Scenario price

AKTX FAQ — answered by Alphio AI

Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Akari Therapeutics PLC (AKTX) is not a good buy. The stock is trading at $7.37, significantly below its 52-week high of $29.32, indicating a substantial decline of 70.66% over the past year. The RSI is at 38.906, suggesting it is nearing oversold territory but not yet a strong buy signal. Furthermore, the forward P/E is 0, reflecting no earnings expected in the near term, which raises concerns about its profitability and financial health. The main risk is the negative net income, which reached -14,455,000 USD in Q1 2026, indicating ongoing financial struggles.

3 analysts cover AKTX: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 3.33.